Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank A Post

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
Sleep|February 16, 2021
Sleep health and cognitive function among people with and without HIV: the use of different machine learning approachesDavide De Francesco, Caroline A Sabin, Alan Winston, et al.
Plos One|July 21, 2021
Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIVDavide De Francesco, Xinzhu Wang, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 24, 2024
Epigenetic associations with kidney disease in individuals of African ancestry with APOL1 high-risk genotypes and HIVRachel K Y Hung, Ricardo Costeira, Junyu Chen, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
HIV Medicine|September 16, 2021
COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in EnglandAlison E Brown, Sara E Croxford, Sophie Nash, et al.
HIV Medicine|January 12, 2024
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UKZoe Ottaway, Lucy Campbell, Laura R Cechin, et al.
Plos Medicine|October 7, 2020
The impact of continuous quality improvement on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-randomised controlled implementation trialH Manisha Yapa, Jan-Walter De Neve, Terusha Chetty, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
Sleep|February 16, 2021
Sleep health and cognitive function among people with and without HIV: the use of different machine learning approachesDavide De Francesco, Caroline A Sabin, Alan Winston, et al.
Plos One|July 21, 2021
Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIVDavide De Francesco, Xinzhu Wang, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 24, 2024
Epigenetic associations with kidney disease in individuals of African ancestry with APOL1 high-risk genotypes and HIVRachel K Y Hung, Ricardo Costeira, Junyu Chen, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
HIV Medicine|September 16, 2021
COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in EnglandAlison E Brown, Sara E Croxford, Sophie Nash, et al.
HIV Medicine|January 12, 2024
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UKZoe Ottaway, Lucy Campbell, Laura R Cechin, et al.
Plos Medicine|October 7, 2020
The impact of continuous quality improvement on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-randomised controlled implementation trialH Manisha Yapa, Jan-Walter De Neve, Terusha Chetty, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Pageof 18